Myriad Genetics is expanding use of its ultrasensitive tumor-informed Precise MRD ctDNA test beyond an early access program. The company said it is rolling the assay out across colorectal and renal cancers in addition to breast cancer, and is using recent evidence from MONITOR-Breast to support broader clinical adoption. Myriad described 154 stage I–III breast cancer patients and 949 longitudinal plasma samples in MONITOR-Breast, reporting that the test predicted pathological complete response with 100% specificity and that end-of-neoadjuvant ctDNA positivity was strongly associated with post-surgery MRD status. With the workflow based on tumor-informed whole-genome sequencing panels tracking up to 1,000 variants, Myriad’s go-to-market push emphasizes MRD evidence generation and integration into oncology care settings.